Isoray, Inc. (ISR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Isoray, Inc. (ISR) trades at $0.38. Isoray, Inc. focuses on developing and marketing isotope-based medical products, primarily Cesium-131 brachytherapy seeds, for cancer treatment. Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for ISR: ISR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ISR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ISR: 1/1 perspectives are bearish.
How is this calculated? →Isoray, Inc. (ISR) Healthcare & Pipeline Overview
Isoray, Inc. specializes in isotope-based medical devices for cancer treatment, focusing on Cesium-131 brachytherapy seeds. With a presence in the United States and internationally, the company addresses cancers such as prostate, brain, and lung, positioning itself in a competitive medical device landscape with a negative profit margin of -12261.7%.
What Is the Investment Thesis for ISR?
Isoray, Inc. presents a focused investment opportunity within the niche market of brachytherapy solutions. The company's Cesium-131 seeds offer a targeted approach to cancer treatment, potentially reducing side effects compared to traditional radiation therapies. However, the company's negative P/E ratio of -3.54, a profit margin of -12261.7%, and a gross margin of -166.3% indicate significant financial challenges. Growth catalysts include expanding clinical applications of Cesium-131 and securing additional regulatory approvals. The investment thesis hinges on Isoray's ability to improve its financial performance through increased sales, cost management, and strategic partnerships. Key risks involve competition from alternative cancer treatments and the company's ability to achieve profitability.
Based on FMP financials and quantitative analysis
ISR Key Highlights
- Isoray specializes in Cesium-131 brachytherapy seeds for targeted cancer treatment.
- The company's products address a range of cancers, including prostate, brain, lung, and gynecological cancers.
- Isoray operates in the United States and internationally, expanding its market reach.
- The company faces financial challenges, indicated by a negative profit margin of -12261.7%.
- Isoray's P/E ratio is -3.54, reflecting its current lack of profitability.
Who Are ISR's Competitors?
ISR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASXC Asensus Surgical, Inc. | $0.35 | +0.64% | $94.92M | 53 |
| CYT Cyteir Therapeutics, Inc. | $3.02 | -2.27% | $108.71M | 47 |
| FVE Five Star Senior Living Inc. | $2.94 | +2.44% | $98.39M | 39 |
| GENE Genetic Technologies Limited | $0.77 | +0.00% | $111.24M | 43 |
| HLVX HilleVax, Inc. | $2.09 | -0.48% | $104.76M | 47 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ISR's Key Strengths?
- Proprietary Cesium-131 brachytherapy seeds.
- Targeted cancer treatment approach.
- Established relationships with medical facilities.
- Presence in the United States and internationally.
What Are ISR's Weaknesses?
- Negative profit margin.
- Limited product portfolio.
- Reliance on a single isotope (Cesium-131).
- Small market capitalization.
What Could Drive ISR Stock Higher?
- Potential regulatory approvals for new clinical applications of Cesium-131.
- Expansion of strategic partnerships with hospitals and cancer centers.
- Continued research and development efforts to improve product offerings.
What Are the Key Risks for ISR?
- Negative return on equity (-41.8%) — the business is not currently generating profit on shareholder capital.
- Competition from alternative cancer treatments.
- Regulatory changes affecting brachytherapy procedures.
- Dependence on a single isotope (Cesium-131).
- Financial challenges related to profitability and cash flow.
What Are the Growth Opportunities for ISR?
- Expanding Clinical Applications: Isoray has the opportunity to expand the clinical applications of its Cesium-131 seeds beyond prostate cancer. This includes targeting other cancers such as brain, lung, and gynecological cancers. The market for these indications represents a significant growth opportunity, with the global market for lung cancer therapeutics projected to reach $44.6 billion by 2030. Success in these areas would require clinical trials and regulatory approvals, but could significantly increase Isoray's revenue and market share.
- Strategic Partnerships and Collaborations: Isoray can pursue strategic partnerships with hospitals, cancer centers, and research institutions to promote the adoption of its Cesium-131 seeds. Collaborations can facilitate clinical trials, expand market access, and enhance the company's reputation. For example, partnering with leading cancer centers could accelerate the adoption of Isoray's technology and drive revenue growth. These partnerships can also help in developing new treatment protocols and expanding the use of Cesium-131 in combination with other therapies.
- International Expansion: Isoray has the opportunity to expand its international presence by entering new markets in Europe, Asia, and Latin America. The global market for brachytherapy is expected to grow, driven by increasing cancer incidence and demand for minimally invasive treatments. Entering new markets would require regulatory approvals and establishing distribution networks, but could significantly increase Isoray's revenue and market share. The company can focus on countries with favorable healthcare policies and a growing demand for advanced cancer treatments.
- Product Innovation and Development: Isoray can invest in research and development to develop new products and improve its existing Cesium-131 seeds. This includes developing new delivery systems, enhancing the seeds' radiation profile, and exploring the use of Cesium-131 in combination with other therapies. Innovation can help Isoray maintain its competitive advantage and attract new customers. The company can also focus on developing products that address unmet needs in the cancer treatment market.
- Acquisitions and Mergers: Isoray could explore acquisitions or mergers with other companies in the medical device or cancer treatment space. This could provide access to new technologies, markets, and distribution channels. For example, acquiring a company with complementary products or a strong presence in a specific geographic region could accelerate Isoray's growth and expand its market reach. However, any acquisition or merger would need to be carefully evaluated to ensure it aligns with Isoray's strategic goals and financial capabilities.
What Opportunities Does ISR Have?
- Expanding clinical applications of Cesium-131.
- Strategic partnerships and collaborations.
- International expansion into new markets.
- Product innovation and development.
What Threats Does ISR Face?
- Competition from alternative cancer treatments.
- Regulatory changes and approvals.
- Technological advancements in radiation therapy.
- Economic downturns affecting healthcare spending.
What Are ISR's Competitive Advantages?
- Proprietary Cesium-131 technology.
- Established relationships with hospitals and physicians.
- Regulatory approvals for specific cancer treatments.
What Does ISR Do?
Isoray, Inc., through its subsidiary IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. Founded in 1998 and based in Richland, Washington, the company's primary offering is CS-1 Cesium-131 brachytherapy seeds. These seeds are used in brachytherapy, a form of radiation therapy where the radioactive source is placed inside or near the area requiring treatment. Isoray's products target a range of cancers, including prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. The company sells its products to facilities and physician practices that utilize various surgical facilities. Isoray aims to provide precise and targeted cancer treatment options, minimizing damage to surrounding healthy tissue. The company operates in the United States and internationally, focusing on expanding its market reach and product applications within the brachytherapy space. Despite its innovative product offerings, Isoray faces challenges related to profitability, as reflected in its negative profit and gross margins.
What Products and Services Does ISR Offer?
- Develops isotope-based medical products for cancer treatment.
- Manufactures Cesium-131 brachytherapy seeds.
- Sells products to facilities and physician practices.
- Targets prostate, brain, lung, and other cancers.
- Offers a form of radiation therapy called brachytherapy.
- Operates in the United States and internationally.
How Does ISR Make Money?
- Develops and manufactures Cesium-131 brachytherapy seeds.
- Sells seeds to hospitals, clinics, and physician practices.
- Generates revenue through direct sales and distribution agreements.
What Industry Does ISR Operate In?
Isoray operates within the medical device industry, specifically in the cancer treatment segment. The market for cancer therapies is substantial and growing, driven by an aging population and advancements in medical technology. Brachytherapy, while a smaller segment compared to chemotherapy and external beam radiation, offers a targeted treatment approach. The competitive landscape includes companies offering various radiation therapy solutions and surgical interventions. Isoray's focus on Cesium-131 seeds positions it within a niche market, but it faces competition from alternative brachytherapy isotopes and other cancer treatment modalities. The industry is characterized by stringent regulatory requirements and the need for continuous innovation to improve treatment outcomes.
Who Are ISR's Key Customers?
- Hospitals and cancer centers.
- Radiation oncologists and surgeons.
- Physician practices specializing in cancer treatment.
Company Profile
Isoray, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Richland, US. The company is led by CEO Lori A. Holmes-Woods. ISR has traded publicly since 2002.
ROE -42%Key Financial Metrics
Return on equity for Isoray, Inc. stands at -41.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -27.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -40.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.75 indicates the company holds enough short-term assets to cover its near-term obligations.
Net buyingInsider Activity
The most recent 12 insider filings for Isoray, Inc. break down as 0 sales and 12 purchases. On net that is roughly 7.0M shares acquired (about $1.7M) — insiders putting money in tends to read as conviction.
ISR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Isoray's future, indicating that key executives believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting successful clinical trials and advancements in their product pipeline.
- Analysts have noted increased interest in Isoray's innovative treatments, which are gaining traction in the medical field.
- The company's strategic partnerships have expanded, enhancing its market presence and credibility in the healthcare sector.
Bear Case
- Concerns about regulatory hurdles remain, as the medical device industry is often scrutinized, which could delay product launches.
- Social sentiment reflects skepticism regarding the scalability of Isoray's technology, with some investors questioning its market adoption.
- Recent earnings reports have shown mixed results, leading to uncertainty about the company's financial health and growth trajectory.
- Competition in the medical sector is intensifying, with new entrants potentially overshadowing Isoray's offerings and market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ISR Latest News
-
Stocks That Hit 52-Week Highs On Monday
· Dec 2, 2019
ISR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ISR.
Price Targets
Wall Street price target analysis for ISR.
ISR MoonshotScore
What does this score mean?
The MoonshotScore rates ISR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lori A. Holmes-Woods
CEO
Lori A. Holmes-Woods serves as the CEO of Isoray, Inc. Her background includes extensive experience in the healthcare industry, with a focus on medical devices and oncology. She has held leadership positions in various companies, contributing to strategic planning, product development, and market expansion. Holmes-Woods' expertise spans across commercial operations, regulatory affairs, and financial management. Her career reflects a commitment to advancing cancer treatment options and improving patient outcomes. She is responsible for managing 66 employees.
Track Record: Under Lori A. Holmes-Woods' leadership, Isoray has focused on expanding the clinical applications of its Cesium-131 seeds and strengthening its relationships with key medical facilities. She has overseen efforts to secure regulatory approvals and expand the company's market presence. Key milestones include strategic partnerships and product development initiatives aimed at improving treatment outcomes and driving revenue growth. Her tenure has been marked by a focus on innovation and strategic execution.
ISR Healthcare Stock FAQ
What does Isoray, Inc. do?
Isoray, Inc. develops, manufactures, and sells isotope-based medical products, primarily Cesium-131 brachytherapy seeds, for the treatment of cancer. These seeds are used in brachytherapy, a form of radiation therapy where the radioactive source is placed inside or near the area requiring treatment. Isoray's products target a range of cancers, including prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. The company sells its products to facilities and physician practices in the United States and internationally, aiming to provide precise and targeted cancer treatment options.
What do analysts say about ISR stock?
Analyst coverage of Isoray, Inc. (ISR) is limited, but the stock is generally viewed as a high-risk, high-reward investment due to its small market capitalization and niche market focus. Key valuation metrics, such as the P/E ratio of -3.54 and negative profit margins, reflect the company's current lack of profitability. Growth considerations include the potential for expanding clinical applications of Cesium-131 and securing additional regulatory approvals. Investors should carefully consider the company's financial challenges and competitive landscape before investing.
What are the main risks for ISR?
Isoray, Inc. faces several key risks, including competition from alternative cancer treatments, regulatory changes affecting brachytherapy procedures, and dependence on a single isotope (Cesium-131). The company's financial challenges, as indicated by its negative profit margin and P/E ratio, also pose a significant risk. Additionally, technological advancements in radiation therapy could render Isoray's products obsolete. Investors should carefully evaluate these risks before investing in ISR.
How does Isoray, Inc. navigate regulatory approval processes?
Isoray, Inc. navigates regulatory approval processes by adhering to stringent guidelines set by regulatory bodies like the FDA in the United States. The company must demonstrate the safety and efficacy of its Cesium-131 brachytherapy seeds through clinical trials and preclinical studies. Maintaining compliance with quality control standards and manufacturing practices is crucial for securing and maintaining regulatory approvals. Isoray's regulatory strategy involves continuous monitoring of regulatory changes and proactive engagement with regulatory agencies to ensure timely approvals for new products and indications.
How does Isoray, Inc. manage patent expiration risks?
Isoray, Inc. manages patent expiration risks by continuously innovating and developing new technologies related to its Cesium-131 brachytherapy seeds. The company actively seeks to extend its intellectual property protection through new patents on product enhancements, delivery systems, and treatment protocols. Additionally, Isoray focuses on building strong relationships with key opinion leaders and medical facilities to establish a competitive advantage beyond patent protection. This strategy aims to mitigate the impact of potential biosimilar competition and maintain market share.
What are the key factors to evaluate for ISR?
Evaluate ISR on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does ISR data refresh on this page?
ISR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ISR's recent stock price performance?
Isoray, Inc. (ISR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Cesium-131 brachytherapy seeds. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be outdated.
- AI analysis is pending and may provide further insights.